Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study.
Emanuela PalmeriniLaura PazzagliaLuca CevolaniLoredana PratelliMichela PieriniIrene QuattriniElisa CarrettaMaria Cristina ManaraMichela PaselloGiorgio FregaAnna PaioliAlessandra LonghiMarilena CesariRossella HakimToni IbrahimLaura CampanacciEric Lodewijk StaalsDavide Maria DonatiMaria Serena BenassiKatia ScotlandiStefano FerrariPublished in: Cancers (2022)
Denosumab induces ALP/OCN and s-CTX reduction. High baseline s-CTX identifies a group of patients at higher risk of progression of the disease.